Vizionfocus, Inc. AI Stock Analysis
Vizionfocus, Inc. (4771) AI Stock Analysis
Vizionfocus, Inc.
(TWSE:4771)
Vizionfocus scores well on the strength of its financial performance and valuation. The company has delivered multi-year revenue and profit compounding with expanding gross margins, high profitability, and a balance sheet that has been significantly strengthened through lower leverage and a larger equity base. That fundamental quality is available at an undemanding P/E of 11.9 with a 3.5% dividend yield, a combination that supports the score. Offsetting this, free cash flow turned slightly negative in 2025 as aggressive capacity investment consumed all operating cash, while operating margin and ROE have drifted lower — the growth is partly externally funded rather than self-financed. Technicals are the softest input: the stock trades below its 20- and 50-day averages with a negative MACD and neutral RSI, indicating near-term consolidation, though it remains above its 200-day average in a longer-term uptrend. Earnings call and corporate event data were unavailable and excluded, with their weight redistributed across the remaining components.
Vizionfocus, Inc. (4771) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 10.51B
- Dividend Yield
- 3.87%
- Average Volume (3M)
- 222.84K
- Price to Earnings (P/E)
- 11.1
- Beta (1Y)
- 0.51
- Revenue Growth
- 31.09%
- EPS Growth
- 33.78%
- Country
- TW
- Employees
- 486
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Instruments & Supplies
Vizionfocus, Inc. Business Overview & Revenue Model
Company Description
Established in 2011 and based in Miaoli, Taiwan, Vizionfocus Inc. operates as a manufacturer of various sophisticated products. The company primarily produces medical equipment, serving key markets across Taiwan, China, Japan, and the United States....
Vizionfocus, Inc. Financial Statement Overview
Summary
Strong overall financial profile led by an exceptional income statement (score 86): revenue more than quadrupled since 2020 to roughly NT$3.49 billion, net income reached NT$741 million, and gross margin expanded to about 41%, with net margin above 21% and EBITDA margin above 40%. The balance sheet (score 79) has been materially de-risked, with debt-to-equity down to about 0.40, equity funding roughly 56% of assets, and ROE near 19%. The weak link is cash flow (score 58): heavy capacity-related capital spending absorbed all NT$1.07 billion of operating cash, pushing free cash flow to negative NT$78 million in 2025, while operating margin slipped from 33% to 29% and ROE fell from about 31% on an enlarged equity base. Execution on the expansion and a return to durable positive free cash flow are the key watch items.
Income Statement
86Very PositiveBalance Sheet
79PositiveCash Flow
58Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.03B | 3.49B | 3.00B | 2.57B | 1.83B | 1.42B |
| Gross Profit | 1.66B | 1.43B | 1.18B | 1.03B | 697.43M | 491.81M |
| EBITDA | 1.55B | 1.42B | 1.30B | 1.13B | 748.91M | 500.02M |
| Net Income | 915.25M | 740.77M | 669.59M | 562.28M | 312.99M | 234.13M |
Balance Sheet | ||||||
| Total Assets | 8.16B | 7.06B | 5.94B | 4.46B | 3.21B | 2.89B |
| Cash, Cash Equivalents and Short-Term Investments | 1.09B | 1.29B | 1.43B | 800.16M | 918.50M | 580.88M |
| Total Debt | 1.81B | 1.59B | 1.34B | 1.73B | 763.60M | 785.18M |
| Total Liabilities | 3.53B | 2.64B | 2.09B | 2.43B | 1.19B | 1.08B |
| Stockholders Equity | 4.14B | 3.98B | 3.53B | 1.79B | 1.64B | 1.42B |
Cash Flow | ||||||
| Free Cash Flow | -635.71M | -78.24M | 197.41M | -435.20M | 465.69M | -51.61M |
| Operating Cash Flow | 1.18B | 1.07B | 1.14B | 958.65M | 757.76M | 388.97M |
| Investing Cash Flow | -1.62B | -1.23B | -1.21B | -1.39B | -288.21M | -392.68M |
| Financing Cash Flow | 121.03M | -47.06M | 426.19M | 325.25M | -133.98M | 280.26M |
Vizionfocus, Inc. Peers Comparison
Overall Rating
TW:477174Outperform
TW:321873Outperform
TW:666764.1Neutral
TW:490859Neutral
TW:620952Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 74Outperform | TWD 10.63B | 11.11 | ― | 3.87% | 31.09% | 33.78% | |
| 73Outperform | TWD 10.68B | 9.40 | ― | 6.15% | 0.24% | 28.93% | |
| 64Neutral | TWD 12.62B | 12.58 | ― | 4.56% | 28.55% | 55.47% | |
| 59Neutral | TWD 13.26B | 72.71 | ― | 0.57% | 4.39% | 9.57% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 52Neutral | TWD 13.55B | 33.30 | ― | 0.63% | 66.86% | ― |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:4771 | Vizionfocus, Inc. | 180.00 | 6.94 | 4.01% | |
| TW:3218 | Universal Vision Biotechnology Co., Ltd. | 126.00 | -20.80 | -14.17% | |
| TW:4908 | APAC Opto Electronics Inc. | 175.50 | 99.20 | 130.03% | |
| TW:6209 | Kinko Optical Co. Ltd. | 78.50 | 30.15 | 62.34% | |
| TW:6667 | Trusval Technology Co., Ltd. | 249.00 | 20.12 | 8.79% | |
| TW:7932 | e-Ray Technology Co., Ltd. | 201.50 | -193.50 | -48.99% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026
